Skip to main content
Bioversys N logo

Bioversys N — Investor Relations & Filings

Ticker · BIOV ISIN · CH0210362643 LEI · 894500UFIGC75NPZEZ68 SW Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2025-07-10 Regulatory Filings
Country CH Switzerland
Listing SW BIOV

About Bioversys N

https://www.bioversys.com/

Bioversys is a clinical-stage biopharmaceutical company focused on the research and development of novel antibacterial therapies to combat the global threat of antimicrobial resistance (AMR). The company develops small molecule drugs that act on novel bacterial targets through innovative modes of action. Its clinical pipeline includes BV100, a treatment for serious hospital infections caused by Acinetobacter baumannii, and Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB). Both candidates are in Phase 2 clinical development. The company's earlier-stage portfolio includes BV200, an anti-virulence compound for Staphylococcus aureus infections, and BV500 for Nontuberculous mycobacteria (NTM) infections, addressing critical unmet medical needs.

Recent filings

Filing Released Lang Actions
Commercial register
Regulatory Filings Classification · 1% confidence The document is an official extract from the Swiss Commercial Register (Handelsregisteramt des Kantons Basel-Stadt) for the company BioVersys AG. It details the company's history of capital changes, share structure, and corporate governance amendments. Since this is a regulatory filing from a government authority regarding the company's legal status and capital structure, and it does not fit into specific categories like '10-K' or 'ER', it is classified as a Regulatory Filing (RNS).
2025-07-10 English
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
Regulatory Filings Classification · 1% confidence The document is titled 'Ad-hoc' and explicitly states 'Release of an ad hoc announcement pursuant to Art. 53 LR'. It details a significant business event: a global research collaboration and exclusive license option agreement between BioVersys and Shionogi, including financial terms (upfront payments, milestones, royalties). This type of announcement, which is material non-public information released outside of scheduled reporting periods, typically falls under general regulatory disclosure requirements. Since it is not a specific financial report (10-K, IR, ER), a management change (MANG), a director's dealing (DIRS), or a capital event (CAP/SHA), the most appropriate general category for a significant, non-standard regulatory disclosure is 'Regulatory Filings' (RNS). The document length is substantial enough (over 11,000 characters) that it is the primary announcement itself, not just a notice of publication (RPA).
2025-07-02 English
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
M&A Activity Classification · 1% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and details a 'Global Research Collaboration' and 'exclusive license option agreement' between BioVersys AG and Shionogi. This type of announcement, which details a significant business development (partnership, licensing deal, major financial terms), is typically classified as a material event disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it relates to a strategic business transaction, it fits best under the general category for significant corporate news that isn't strictly financial reporting or insider trading. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a non-standard, material ad hoc announcement, especially since it references 'Art. 53 LR' (likely a listing rule requirement for immediate disclosure). It is not a proxy statement (DEF 14A), a capital change (CAP/SHA), or a director dealing (DIRS). It is a material business update, best categorized as RNS.
2025-07-02 English
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
AGM Information Classification · 1% confidence The document is explicitly titled "BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS" and details the outcomes of the AGM held on June 27, 2025. It mentions shareholder votes, the approval of the 2024 Annual Report, and board re-elections. This content directly corresponds to the definition of AGM Information (AGM-R). Although it mentions the Annual Report, the primary focus and context of the announcement is the meeting results, not the full report itself. Therefore, AGM-R is the most appropriate classification.
2025-06-30 English
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
AGM Information Classification · 1% confidence The document explicitly announces the 'RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS' (AGM). It details that all agenda items passed, including the approval of the 2024 Annual Report, re-election of board members, and capital structure amendments. This content directly relates to the proceedings and outcomes of the AGM. Although the Annual Report is mentioned as an approved item, the primary purpose of this specific filing is to report the results of the shareholder vote, making 'AGM Information' (AGM-R) the most appropriate classification. It is not the full Annual Report (10-K) itself, nor is it solely a declaration of voting results (DVA), as it includes commentary and context about board changes and future strategy related to the meeting.
2025-06-30 English
Article of Association
AGM Information Classification · 1% confidence The document is titled 'Statuten der BioVersys AG / Articles of Association of BioVersys Ltd'. It outlines the company's legal structure, share capital, purpose, and governance rules (such as capital bands and share issuance procedures). This is a foundational corporate governance document that defines the company's internal rules and board authorities. In the context of the provided categories, 'Governance Information' (CGR) is the most accurate classification for a company's Articles of Association.
2025-06-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.